Medical Health & Life Science Research News

Research report explores the genetic disorder cluster muscular dystrophy therapeutic and drug pipeline review H1

Research report explores the genetic disorder cluster muscular dystrophy therapeutic and drug pipeline review H1

This report provides an overview of the genetic disorders pipeline landscape, specifically focusing on muscular dystrophies.

- Advertisement -

- Restart your WhaTech membership at anytime. -

Summary

This report provides an overview of the genetic disorders pipeline landscape, specifically focusing on muscular dystrophies Make an Inquiry about this news. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Becker and Duchenne Muscular Dystrophy (BMD and DMD) and features dormant and discontinued projects.

Both indications covered are inherited muscular dystrophies, a group of genetic, degenerative diseases primarily affecting voluntary muscles.

GET SAMPLE REPORT @        https://www.wiseguyreports.com/sample-request/1291964-genetic-disorder-cluster-muscular-dystrophy-drug-development-pipeline-review-2017

BMD, the first type of muscular dystrophy, leads to symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

- Advertisement -

- Restart your WhaTech membership at anytime. -
DMD is a condition which causes muscle weakness, and is an X-linked disorder.

The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin.

Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy.

They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

The size of these two pipelines ranges from just six in BMD to 108 in DMD. The majority of pipeline products for DMD target dystrophin which, as mentioned, is the causative gene for the disease.

However, a number of products act on other molecular targets such as growth differentiation factor 8, nuclear factor kappa B and utrophin. The first two of these make up the pipeline for BMD, along with forkhead box protein 1B.

Scope

- Which companies are the most active within the pipeline for genetic disorder therapeutics?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in the field of genetic disorder therapeutics?

Reasons to access

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

Executive Summary 3

Table of Contents 4

List of Tables 5

List of Figures 7

Introduction 8

Genetic Disorder Cluster Muscular Dystrophy Report Coverage 8

Becker Muscular Dystrophy – Overview 8

Duchenne Muscular Dystrophy – Overview 8

Therapeutics Development 9

Becker Muscular Dystrophy 9

Duchenne Muscular Dystrophy 12

Therapeutics Assessment 22

Becker Muscular Dystrophy 22

Duchenne Muscular Dystrophy 30

Companies Involved in Therapeutics Development 38

Becker Muscular Dystrophy 38

Duchenne Muscular Dystrophy 40

Dormant Projects 63

Becker Muscular Dystrophy 63

Duchenne Muscular Dystrophy 64

Discontinued Products 66

Duchenne Muscular Dystrophy 66

Product Development Milestones 67

Duchenne Muscular Dystrophy 67

…Continued        

 

ACCESS REPORT @ www.wiseguyreports.com/reports/129…eline-review-2017 Make an Inquiry about this news  

News From

Wise Guy Reports - Market ResearchWise Guy Reports
Category: Market Research Publishers and RetailersCompany profile: Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs. Our Market Research Reports and Consulting Services  ...

For more information:

Make an Inquiry about this report HERE!
  • www.wiseguyreports.com/reports/129…eline-review-2017
  • www.wiseguyreports.com/sample-requ…eline-review-2017
  • www.linkedin.com/company/4828928?t…9%2Ctas%3Awiseguy
  • twitter.com/WiseGuyReports
  • www.facebook.com/Wiseguyreports-10…69213183/?fref=ts